Precision biosciences stock.

Mar 13, 2023 · Currently, the analyst consensus on Precision BioSciences is a Moderate Buy with an average price target of $10.50. See the top stocks recommended by analysts >> DTIL market cap is currently $101 ...

Precision biosciences stock. Things To Know About Precision biosciences stock.

8 thg 3, 2019 ... Precision BioSciences Stock Offered in IPO · Unwanted on- and off-target DNA modifications. · Inability to efficiently and precisely introduce ...28 thg 3, 2019 ... Precision Biosciences, the gene-editing startup, started trading on the Nasdaq stock exchange today after raising a $126.4 million IPO ...When it comes to precision cutting, having the right tool can make all the difference. That’s where the Super Cutter comes in. This innovative tool is designed to provide unparalleled accuracy and precision, making it a must-have for any DI...Currently, the analyst consensus on Precision BioSciences is a Moderate Buy with an average price target of $10.50. See today’s best-performing stocks on TipRanks >> The company has a one-year ...

Avidity Biosciences ( RNA) stock is jumping over 15% in early trading after announcing that its alliance with Bristol-Myers Squibb ( BMY) had been greatly …DURHAM, N.C.--(BUSINESS WIRE)--Nov. 30, 2023-- Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel …

Nov 14, 2019 · Shares of Precision BioSciences (DTIL 0.23%) ... As of 1:40 p.m. EST, the stock had settled to a 16.9% gain. The gene-editing stock is up 70% since the beginning of November.

Earnings Summary. For their last quarter, Precision BioSciences (DTIL) reported earnings of -$0.10 per share, beating the Zacks Consensus Estimate of $-0.19 per share. This reflects a positive ...Precision BioSciences Inc Registered Shs's market capitalization is $46.27 M by 120.90 M shares outstanding. Precision BioSciences Stock Snapshot 3.34June 23, 2022 at 12:08 PM · 3 min read. Shares of Precision BioSciences, Inc. DTIL have remained up so far this week as the company has entered into an exclusive worldwide in vivo gene-editing ...7 ngày trước ... DURHAM, N.C.–(BUSINESS WIRE)–Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ...

Dec 15, 2020 · Under the terms of the agreement, Precision will receive an upfront cash payment of $100 million, as well as an equity investment by Lilly of $35 million in Precision's common stock. Precision is ...

Patrick Trucchio, an analyst from H.C. Wainwright, reiterated the Buy rating on Precision BioSciences (DTIL – Research Report). The associated price target is $3.00. Patrick Trucchio has given ...

If you want to keep up to date on the stock market you have a device in your pocket that makes that possible. Your phone can track everything finance-related and help keep you up to date on the world markets.Dec 1, 2023 · About the Company. Precision BioSciences, Inc., a clinical stage gene editing company, develops ex vivo allogeneic chimeric antigen receptor (CAR) T immunotherapies and in vivo therapies for genetic and infectious diseases in the United States. The company offers ARCUS, a genome editing platform to cure genetic disorders. Nov 7, 2023 · The stock currently has a share float of 51.43%. Precision Biosciences Inc stock is held by 114 institutions, with Great Point Partners LLC being the largest institutional investor. By Jun 29, 2023, it held 6.49% of the shares, which is about 7.47 million shares worth $3.93 million. Precision Biosciences Inc (NASDAQ:DTIL)’s traded shares stood at 0.64 million during the latest session, with the company’s beta value hitting 1.50. At the last check today, the stock’s price was $0.41, to imply a decrease of -3.21% or -$0.01 in intraday trading. The DTIL share’s 52-week ...The 2030 consensus revenue estimate for Precision Biosciences is $400 million. That feels aggressive but plausible if the company’s pipeline develops and commercializes as expected.Precision BioSciences (DTIL) Company Description: Precision BioSciences, Inc. is a biotechnology company, which engages in the development of genome editing technologies. It operates through the ...

Precision BioSciences to Present at Upcoming Sidoti Conference. DURHAM, N.C., November 10, 2023--Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion, excision, and …Founders Derek Jantz, Jeff Smith, Matthew Kane. Operating Status Active. Last Funding Type Post-IPO Equity. Legal Name Precision BioSciences, Inc. Stock Symbol NASDAQ:DTIL. Company Type For Profit. Contact Email [email protected]. Phone Number +1 919 314-5512. Precision …Aug 15, 2023 · DURHAM, N.C., August 15, 2023--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based in vivo gene editing therapies, today announced completion ... Precision BioSciences, Inc. (Nasdaq: DTIL), is a clinical stage biotechnology company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing …Nov 24, 2023 · Checkpoint Therapeutics (NASDAQ:CKPT) and Precision BioSciences (NASDAQ:DTIL) are both small-cap medical companies, but which is the better investment?We will compare the two businesses based on the strength of their community ranking, risk, dividends, profitability, earnings, analyst recommendations, institutional ownership, valuation and media sentiment. In a report released on November 4, Justin Zelin from BTIG reiterated a Buy rating on Precision BioSciences (DTIL - Research Report), with a price target of $8.00.The companys shares closed last ...

Precision BioSciences Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Provides Business Update. March 15, 2022 at 7:00 AM EDT. ... Weighted average shares of common stock outstanding - basic and diluted 58,688,102 52,031,740 Precision Biosciences, Inc. Consolidated Balance Sheets Data ...

Valuation metrics show that Precision BioSciences, Inc. may be undervalued. Its Value Score of B indicates it would be a good pick for value investors. The financial health and growth prospects of ...Research Precision BioSciences' (Nasdaq:DTIL) stock key valuation metrics while comparing it with its industry peers & market side by side. Dashboard Markets Discover Watchlist Portfolios Screener Precision BioSciences, Inc.Precision BioSciences, Inc is a clinical-stage gene editing company. It is developing ex vivo allogeneic chimeric antigen receptor (CAR) T immunotherapies and in vivo therapies for genetic and infectious diseases with the application of its owned ARCUS genome editing platform.JonesTrading analyst Soumit Roy maintained a Buy rating on Precision BioSciences (DTIL – Research Report) today and set a price target of $4.00.The company’s shares opened today at $0.57. Roy ...Additionally, Precision announced a common stock offering yesterday. The company will “sell 35,971,224 shares of its common stock at a price of $1.39 per share.”Precision BioSciences has a consensus target price of $3.00, suggesting a potential upside of 710.81%. Given Precision BioSciences' stronger consensus rating and higher possible upside, equities research analysts clearly believe Checkpoint Therapeutics is more favorable than Precision BioSciences.Precision BioSciences Announces $50 Million Offering of Common Stock. June 21, 2022 05:25 PM Eastern Daylight Time. DURHAM, N.C.-- ( BUSINESS WIRE )--Precision BioSciences, Inc. (Nasdaq: DTIL), a ...Precision BioSciences, Inc. Common Stock (DTIL) Pre-Market Stock Quotes - Nasdaq offers pre-market quotes and pre-market activity data for US and global markets.

Precision BioSciences, Inc. (Nasdaq: DTIL) announced financial results for Q3 2023, focusing on in vivo gene editing pipeline, ... Weighted average shares of common stock outstanding-basic and diluted 115,174,752 110,849,196 Precision Biosciences, Inc. Condensed Balance Sheets Data ...

Precision BioSciences, Inc. (DTIL) Stock Price | Stock Quote Nasdaq - MarketScreener PRECISION BIOSCIENCES, INC. Precision BioSciences, Inc. Stock …

Precision BioSciences' CEO is Michael Amoroso, appointed in Oct 2021, has a tenure of 2.08 years. total yearly compensation is $4.37M, comprised of 13.8% salary and 86.2% bonuses, including company stock and options. directly owns 0.2% of the company’s shares, worth $81.33K. The average tenure of the management team and the board of …Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion, excision, and elimination, today announced that, on November 21, 2023, the Compensation Committee of Precision’s Board ...Shares of Precision BioSciences (DTIL 0.23%) ... As of 1:40 p.m. EST, the stock had settled to a 16.9% gain. The gene-editing stock is up 70% since the beginning of November.Nov 28, 2023 · The inducement, part of their Inducement Award Plan, allows the employee to purchase 160,000 shares of Precision BioSciences' common stock at $0.42 each. The stock option comes with a vesting ... View Precision BioSciences, Inc DTIL investment & stock information. Get the latest Precision BioSciences, Inc DTIL detailed stock quotes, stock data, Real-Time ECN, charts, stats and more.Dec 1, 2023 · A high-level overview of Precision BioSciences, Inc. (DTIL) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. On December 4, 2023, Precision Biosciences made a groundbreaking announcement in the esteemed journal Nature Metabolism. The publication highlighted their latest …About Precision BioSciences, Inc. Precision BioSciences, Inc. is a clinical stage biotechnology company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform. ARCUS is a highly specific and versatile genome editing platform that was designed with therapeutic safety, delivery, and control …

DURHAM, N.C., November 07, 2023 -- ( BUSINESS WIRE )--Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in ...If you’re just getting started, tracking investments might seem like a mystery. Thankfully, modern tools and technology make it easier than ever to figure out how to manage your stock portfolio and to track it. This quick guide gives you ti...Precision BioSciences, Inc. is a clinical stage biotechnology company dedicated to improving life (DTIL) with its novel and proprietary ARCUS ® genome editing platform. ARCUS is a highly specific ...Why Is Precision BioSciences Stock Soaring Today? msn.com - August 16 at 3:33 PM: Analysts Just Published A Bright New Outlook For Precision BioSciences, Inc.'s (NASDAQ:DTIL) finance.yahoo.com - August 6 at 8:38 AM: Precision BioSciences Inc Q2 Loss decreases, beats estimates markets.businessinsider.com - August 4 at 11:50 PMInstagram:https://instagram. fatima shrine portugalequity futures vs equity optionssilver penny 1943 priceemerson electric company stock Get the latest information on Precision BioSciences Inc (DTIL), a biotechnology company that develops and commercializes genomic tests for cancer and other diseases. See its stock price, performance, financials, outlook, and news on Google Finance.DURHAM, N.C.--(BUSINESS WIRE)--Jun. 27, 2022-- Precision BioSciences, Inc. (Nasdaq: DTIL) (the “Company”), a clinical stage gene editing company developing ARCUS-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced the closing of an underwritten offering of 35,971,224 shares of its … brokerage firms that accept penny stocksdividend calculator by stock Precision BioSciences, Inc. (NASDAQ:DTIL) shares have had a horrible month, losing 29% after a relatively good period beforehand.For any long-term shareholders, the last month ends a year to forget by locking in a 60% share price decline. After such a large drop in price, Precision BioSciences may be sending very bullish signals at the …The stock currently has a share float of 51.43%. Precision Biosciences Inc stock is held by 114 institutions, with Great Point Partners LLC being the largest institutional investor. By Jun 29, 2023, it held 6.49% of the shares, which is about 7.47 million shares worth $3.93 million. best mobile banking 2023 In the last 3 months, 4 analysts have offered 12-month price targets for Precision BioSciences. The company has an average price target of $3.25 with a high of $5.00 and a low of $2.00.The Precision BioSciences Inc. stock price fell by -9.31% on the last day (Wednesday, 29th Nov 2023) from $0.408 to $0.370. During the last trading day the stock fluctuated 15.44% from a day low at $0.360 to a day high of $0.416. The price has risen in 6 of the last 10 days and is up by 6.78% over the past 2 weeks.